MY184876A - Pharmaceutical composition for preventing cccdna formation of hepatitis b virus - Google Patents

Pharmaceutical composition for preventing cccdna formation of hepatitis b virus

Info

Publication number
MY184876A
MY184876A MYPI2018000085A MYPI2018000085A MY184876A MY 184876 A MY184876 A MY 184876A MY PI2018000085 A MYPI2018000085 A MY PI2018000085A MY PI2018000085 A MYPI2018000085 A MY PI2018000085A MY 184876 A MY184876 A MY 184876A
Authority
MY
Malaysia
Prior art keywords
hepatitis
virus
preventing
cccdna formation
present
Prior art date
Application number
MYPI2018000085A
Inventor
Ki-Hwan Chang
Yong-Won Shin
Chun-Kyu Ko
Wang-Shick Ryu
Original Assignee
Mogam Inst Biomedical Res
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Inst Biomedical Res, Green Cross Corp filed Critical Mogam Inst Biomedical Res
Publication of MY184876A publication Critical patent/MY184876A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is based on a finding that a hepatitis B virus antibody inhibits binding of a surface antigen (HBsAg) of hepatitis B virus to heparan sulfate proteoglycan, thereby preventing cccDNA formation of the hepatitis B virus. It is expected that utilizing the pharmaceutical composition and the method of preventing cccDNA formation of hepatitis B virus of the present invention can fundamentally treat chronic hepatitis B and also prevent a recurrence of hepatitis in a hepatitis B patient after liver transplant surgery. Further, according to the present invention, a material for preventing or treating hepatitis B can be newly identified by confirming whether cccDNA formation is inhibited or not. In addition, according to the present invention, a treatment supplement capable of being administered in combination with the hepatitis B virus antibody can be newly identified. Figure 3
MYPI2018000085A 2015-07-24 2016-07-22 Pharmaceutical composition for preventing cccdna formation of hepatitis b virus MY184876A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150105277A KR101771309B1 (en) 2015-07-24 2015-07-24 PHARMACEUTICAL COMPOSITION FOR PREVENTING cccDNA FORMATION OF HEPATITIS B VIRUS
PCT/KR2016/008039 WO2017018739A1 (en) 2015-07-24 2016-07-22 Pharmaceutical composition for preventing cccdna formation of hepatitis b virus

Publications (1)

Publication Number Publication Date
MY184876A true MY184876A (en) 2021-04-29

Family

ID=57884746

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018000085A MY184876A (en) 2015-07-24 2016-07-22 Pharmaceutical composition for preventing cccdna formation of hepatitis b virus

Country Status (6)

Country Link
KR (1) KR101771309B1 (en)
CN (1) CN108136009A (en)
BR (1) BR112018001431A2 (en)
EA (2) EA201890362A1 (en)
MY (1) MY184876A (en)
WO (1) WO2017018739A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110859840A (en) * 2019-11-29 2020-03-06 湖南大学 Application of nicotinic acid in preparing medicine for treating chronic hepatitis B
JP2023538630A (en) * 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Use of A1CF inhibitors to treat hepatitis B virus infection
KR102850124B1 (en) 2022-05-31 2025-08-29 재단법인 아산사회복지재단 Pharmaceutical composition comprising sorafenib and DDC for preventing or treating Hepatitis B-Associated hepatocellular carcinoma
CN116804053B (en) * 2023-08-02 2024-01-26 南方医科大学南方医院 anti-HBcAg monoclonal antibody and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505582A (en) * 2001-10-04 2005-02-24 エックステイエル バイオファーマスーティカルズ リミテッド Treatment of hepatitis B virus infection with human monoclonal antibodies
KR100467706B1 (en) 2002-01-15 2005-01-24 주식회사 녹십자홀딩스 Human antibodies against the surface antigen of HBV
KR20090056537A (en) * 2007-11-30 2009-06-03 주식회사 녹십자 Composition for the prevention or treatment of hepatitis V virus infection comprising as an active ingredient an antibody having hepatitis V virus neutralizing ability
CN101642454A (en) * 2009-07-14 2010-02-10 武汉大学 Application of berberine in medicament for treating hepatitis B virus infection
KR101072895B1 (en) * 2009-12-24 2011-10-17 주식회사 녹십자 Human antibodies specifically binding to the Hepatitis B virus surface antigen
CN102631384B (en) * 2012-04-28 2014-03-12 中国科学院武汉病毒研究所 Application of pomegranate in preparing medicament for treating or preventing hepatitis B virus infection
SG11201407970VA (en) * 2012-06-01 2014-12-30 Univ Drexel Modulation of hepatitis b virus cccdna transcription
JP2015002723A (en) * 2013-06-21 2015-01-08 公益財団法人東京都医学総合研究所 HBV-specific artificial DNA nuclease

Also Published As

Publication number Publication date
CN108136009A (en) 2018-06-08
EA201890362A1 (en) 2018-07-31
EA202092397A2 (en) 2021-02-26
EA202092397A3 (en) 2021-06-30
KR20170011863A (en) 2017-02-02
BR112018001431A2 (en) 2018-09-11
WO2017018739A1 (en) 2017-02-02
KR101771309B1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
MX2026001705A (en) Enhanced immune effector cells and use thereof
MX2022010270A (en) A novel approach for treatment of cancer using immunomodulation.
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
MY201148A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2022011756A (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor.
MX2021000289A (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia.
MA49715B1 (en) Oligomers and oligomer conjugates
MX2021014771A (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor.
WO2015200828A8 (en) Conjugates for immunotherapy
GB201014026D0 (en) Treatment
MX386613B (en) Treatment of cancer with immune stimulators
AR111908A1 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT OF HEPATITIS B
MY184876A (en) Pharmaceutical composition for preventing cccdna formation of hepatitis b virus
PH12017501659B1 (en) Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk
PH12018501443A1 (en) Methods of administering hepcidin
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
PH12019501358A1 (en) Methods of administering hepcidin
MX2018011512A (en) Use of insulin for promoting gastric emptying.
MX2018001528A (en) PHARMACEUTICAL COMPOSITION THAT SUMATRIPTAN INCLUDES FOR MIGRAINE TREATMENT.
RU2015122823A (en) METHOD FOR TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH HEPATIC CIRROSIS
SG10201700775YA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
SG10201705954VA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AR106535A1 (en) IMMUNE MODULATION AND TREATMENT OF SOLID TUMORS WITH ANTIBODIES THAT SPECIFICALLY JOIN CD38
EA201991004A1 (en) METHOD FOR TREATING GLYCOGEN ACCUMULATION DISEASE
GR1008805B (en) Solid pharmaceutical composition containing low dose entecavir and method of preparation thereof